Sanofi (NASDAQ:SNY) Given Average Rating of "Buy" by Brokerages

Key Points

• Sanofi has received a consensus rating of "Buy" from ten brokerages, with an average one-year price target of approximately $62.67.
• The company recently reported earnings of $0.90 per share, falling short of estimates, and noted a 7% decline in revenue year-over-year despite beating revenue expectations.
• Institutional investments in Sanofi have increased significantly, with some firms boosting their holdings by over 600% in the recent quarter.

Shares of Sanofi (NASDAQ:SNY - Get Free Report) have been given a consensus recommendation of "Buy" by the ten brokerages that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $62.6667.

A number of analysts have issued reports on the company. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Morgan Stanley raised Sanofi from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Sanofi in a research note on Saturday, September 27th. Finally, Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd.

Sanofi Trading Down 2.3%

Shares of SNY stock opened at $49.71 on Tuesday. The stock's fifty day moving average is $48.20 and its two-hundred day moving average is $49.93. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The firm has a market capitalization of $122.06 billion, a P/E ratio of 11.95, a PEG ratio of 1.24 and a beta of 0.51. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same period last year, the business earned $1.73 earnings per share. The firm's revenue was down 7.0% compared to the same quarter last year. Research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Institutional Trading of Sanofi

A number of hedge funds and other institutional investors have recently modified their holdings of SNY. Ameritas Advisory Services LLC acquired a new stake in shares of Sanofi during the 2nd quarter worth about $28,000. Accent Capital Management LLC acquired a new stake in shares of Sanofi during the 1st quarter worth about $29,000. Eastern Bank increased its position in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after purchasing an additional 300 shares during the last quarter. Banque Transatlantique SA acquired a new stake in shares of Sanofi during the 1st quarter worth about $33,000. Finally, Golden State Wealth Management LLC increased its position in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after purchasing an additional 545 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.